🔗 Share this article Individuals Discontinuing Slimming Medications Regain Pounds Four Times Faster Compared to Those on Conventional Diets Obesity treatment often requires ongoing approaches. New research suggests that patients who come off popular weight-loss injections like Mounjaro or Wegovy may regain reduced body mass much more quickly than those who halt traditional lifestyle programs. Findings released in a prominent medical journal points out that while obese individuals can lose about a fifth of their total mass while on the medication, the weight returns at an average rate of nearly a kilo each month once they quit. "Individuals using such drugs should be cognizant of the danger of rapid rebound weight gain when the therapy concludes," stated researcher Dr. Susan Jebb. Such speed of recovery implies a reversion to starting mass within about a year and a half. Comparing Treatments The research, which looked at dozens of trials involving over 9,000 of participants, contrasted the effects of GLP-1 agonists with older methods. Scientists point out that people who shed pounds through dieting generally experience a less rapid creep back—perhaps 100 grams monthly—after stopping. Explaining the Rapid Regain Doctors propose the way of the injections accounts for the accelerated weight return. The injections copy a natural hormone called glucagon-like peptide-1, which moderates feelings of fullness. "Long-term administration of GLP-1 levels far above than normal could lead to the system to generate a reduced amount of its endogenous GLP-1, and may also lessen responsiveness to its actions," said Dr. Adam Collins, a nutrition specialist. "Withdrawal of this hormone supplement leads to hunger is no longer kept in check, making binge eating a significant risk." A Lifelong Condition? Medical guidelines suggest the jabs for people with weight-linked medical conditions, alongside recommended diet and exercise modifications. Many experts say that, due to the likelihood of relapse, the treatment should be considered ongoing. This view is reinforced by drug manufacturers, who note that the results "emphasize the chronic character of obesity," similar to managing conditions like high blood pressure. User Experiences Individuals who have discontinued the jabs explain a intense return of cravings. "It was like something flipping and you're instantly extremely hungry," said one woman. This challenge is compounded if patients have not established sustainable lifestyle or habit modifications during treatment. Significant Use Survey data show that millions of people in the UK have tried these injections in the past year, with desire being substantial. Use is higher among females compared to men. The 40s and 50s age group shows the greatest usage rates. A large proportion access the medications through private prescriptions rather than public health services. In conclusion, researchers caution that while the jabs are effective tools for shedding pounds, they are not a permanent solution and long-term success relies on integrated lifestyle support.
Obesity treatment often requires ongoing approaches. New research suggests that patients who come off popular weight-loss injections like Mounjaro or Wegovy may regain reduced body mass much more quickly than those who halt traditional lifestyle programs. Findings released in a prominent medical journal points out that while obese individuals can lose about a fifth of their total mass while on the medication, the weight returns at an average rate of nearly a kilo each month once they quit. "Individuals using such drugs should be cognizant of the danger of rapid rebound weight gain when the therapy concludes," stated researcher Dr. Susan Jebb. Such speed of recovery implies a reversion to starting mass within about a year and a half. Comparing Treatments The research, which looked at dozens of trials involving over 9,000 of participants, contrasted the effects of GLP-1 agonists with older methods. Scientists point out that people who shed pounds through dieting generally experience a less rapid creep back—perhaps 100 grams monthly—after stopping. Explaining the Rapid Regain Doctors propose the way of the injections accounts for the accelerated weight return. The injections copy a natural hormone called glucagon-like peptide-1, which moderates feelings of fullness. "Long-term administration of GLP-1 levels far above than normal could lead to the system to generate a reduced amount of its endogenous GLP-1, and may also lessen responsiveness to its actions," said Dr. Adam Collins, a nutrition specialist. "Withdrawal of this hormone supplement leads to hunger is no longer kept in check, making binge eating a significant risk." A Lifelong Condition? Medical guidelines suggest the jabs for people with weight-linked medical conditions, alongside recommended diet and exercise modifications. Many experts say that, due to the likelihood of relapse, the treatment should be considered ongoing. This view is reinforced by drug manufacturers, who note that the results "emphasize the chronic character of obesity," similar to managing conditions like high blood pressure. User Experiences Individuals who have discontinued the jabs explain a intense return of cravings. "It was like something flipping and you're instantly extremely hungry," said one woman. This challenge is compounded if patients have not established sustainable lifestyle or habit modifications during treatment. Significant Use Survey data show that millions of people in the UK have tried these injections in the past year, with desire being substantial. Use is higher among females compared to men. The 40s and 50s age group shows the greatest usage rates. A large proportion access the medications through private prescriptions rather than public health services. In conclusion, researchers caution that while the jabs are effective tools for shedding pounds, they are not a permanent solution and long-term success relies on integrated lifestyle support.